Cost minimization analysis of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants
Journal of the American Pharmacists Association · 2023
DOI: 10.1016/j.japh.2023.06.027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Pharmacists Association, 2023. Verfasst von Jessica S Jay und 8 weiteren Autor:innen. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Kidney Transplantation, Hepatitis C. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Trials describing 4-12 week courses of direct-acting antiviral drugs (DAAs) to treat hepatitis C virus (HCV) transmission from infected donors to uninfected kidney transplant recipients (D+/R-transplants), may be limited in application by costs and delayed access to expensive DAAs. A short prophylactic strategy may be safer and cost-effective. Here, we report a cost minimization analysis using the health system perspective to determine the least expensive DAA regimen, using available published strategies. OBJECTIVES: To conduct cost-minimization analyses (CMAs) from the health system perspective of four DAA regimens to prevent and/or treat HCV transmission from D+/R-kidney transplants. METHODS: CMAs comparing 4 strategies: 1) 7-day prophylaxis with generic sofosbuvir/velpatasvir (SOF/VEL), with 12-week branded glecaprevir/pibrentasvir (G/P) for those with transmission; 2) 8-day branded G/P prophylaxis, with 12-week branded SOF/VEL/voxilaprevir for those with transmission; 3) 4-week perioperative generic SOF/VEL prophylaxis, with 12-week branded G/P for those with transmission; and 4) 8-week branded G/P "transmit-and-treat." We included data from published literature to estimate the probability of viral transmission in patients who received DAA prophylaxis, and assumed a 100% transmission rate for those who received the "transmit-and-treat" approach. RESULTS: In base-case analyses, strategies 1 (expected cost [EC]: $2326) and 2 (expected cost: $2646) were less expensive than strategies 3 (EC: $4859) and 4 (EC: $18,525). Threshold analyses for 7-day SOF/VEL versus 8-day G/P suggested that there were reasonable input levels at which the 8-day strategy may be least costly. The threshold values for the SOF/VEL prophylaxis strategies (7-day vs. 4- week) indicated that the 4-week strategy is unlikely to be less costly under any reasonable value of the input variables. CONCLUSIONS: Short duration DAA prophylaxis using 7 days of SOF/VEL or 8 days of G/P has the potential to yield significant cost savings for D+/R- kidney transplants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Jay, J. S., Patterson, J. A., Zhang, Y., Ijioma, S. C., Carroll, N. V., Holdford, D. A., Sterling, R. K., Gupta, G., & Yakubu, I. (2023). Cost minimization analysis of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants. Journal of the American Pharmacists Association. https://doi.org/10.1016/j.japh.2023.06.027
Vancouver
Jay JS, Patterson JA, Zhang Y, Ijioma SC, Carroll NV, Holdford DA, et al. Cost minimization analysis of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants. Journal of the American Pharmacists Association. 2023. doi:10.1016/j.japh.2023.06.027
BibTeX
@article{Jay2023,
author = {Jay, Jessica S and Patterson, Julie A and Zhang, Yiran and Ijioma, Stephen C and Carroll, Norman V and Holdford, David A and Sterling, Richard K and Gupta, Gaurav and Yakubu, Idris},
title = {Cost minimization analysis of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants},
journal = {Journal of the American Pharmacists Association},
year = {2023},
doi = {10.1016/j.japh.2023.06.027}
}
EUVIMED